ATE299711T1 - Immunologische toleranz induzierende zusammensetzungen enthaltend antigen und mukosale bindende verbindungen - Google Patents

Immunologische toleranz induzierende zusammensetzungen enthaltend antigen und mukosale bindende verbindungen

Info

Publication number
ATE299711T1
ATE299711T1 AT98918742T AT98918742T ATE299711T1 AT E299711 T1 ATE299711 T1 AT E299711T1 AT 98918742 T AT98918742 T AT 98918742T AT 98918742 T AT98918742 T AT 98918742T AT E299711 T1 ATE299711 T1 AT E299711T1
Authority
AT
Austria
Prior art keywords
tolerance
mucosatal
compositions containing
immunological tolerance
binding compounds
Prior art date
Application number
AT98918742T
Other languages
English (en)
Inventor
Jacob Sten Petersen
Original Assignee
Jacob Sten Petersen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacob Sten Petersen filed Critical Jacob Sten Petersen
Application granted granted Critical
Publication of ATE299711T1 publication Critical patent/ATE299711T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98918742T 1997-04-23 1998-04-23 Immunologische toleranz induzierende zusammensetzungen enthaltend antigen und mukosale bindende verbindungen ATE299711T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4418297P 1997-04-23 1997-04-23
US4418497P 1997-04-23 1997-04-23
PCT/US1998/008361 WO1998047529A1 (en) 1997-04-23 1998-04-23 Combinations of antigen and mucosal binding component for inducing specific immunological tolerance

Publications (1)

Publication Number Publication Date
ATE299711T1 true ATE299711T1 (de) 2005-08-15

Family

ID=26721263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98918742T ATE299711T1 (de) 1997-04-23 1998-04-23 Immunologische toleranz induzierende zusammensetzungen enthaltend antigen und mukosale bindende verbindungen

Country Status (8)

Country Link
US (1) US7097845B2 (de)
EP (1) EP0977586B1 (de)
JP (1) JP2001523249A (de)
AT (1) ATE299711T1 (de)
AU (1) AU7161098A (de)
DE (1) DE69830900T2 (de)
DK (1) DK0977586T3 (de)
WO (1) WO1998047529A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9800487D0 (en) 1998-01-09 1998-03-04 Oratol Limited Therapies
WO2001022995A1 (en) * 1999-09-30 2001-04-05 Novo Nordisk A/S A method for preparing conjugates between an antigen and mucosal binding component
CN1927137A (zh) * 2000-01-25 2007-03-14 内布拉斯加大学董事委员会 抵制抗供体免疫的移植前适应器官
US7897575B2 (en) * 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia
DK1450855T3 (da) * 2001-05-23 2010-01-11 Duotol Ab Undertrykkelse af allergiske reaktioner ved hjælp af transdermal indgivelse af allergener i forbindelse med eller konjugeret til toxin-underenheder eller fragmenter deraf
EP2264065B1 (de) 2003-08-05 2017-03-08 Novo Nordisk A/S Neue insulinderivate
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
AU2011252127B2 (en) * 2010-05-10 2014-02-20 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
EP2991672A1 (de) 2013-04-30 2016-03-09 Novo Nordisk A/S Neuartiges verabreichungsschema
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
AR124877A1 (es) * 2021-02-16 2023-05-17 Applied Molecular Transport Inc Composiciones orales sólidas con zinc

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666837A (en) 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
AU596961B2 (en) * 1985-03-08 1990-05-24 Takeda Chemical Industries Ltd. Saccharide digestion inhibiting composition
JP2512796B2 (ja) 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド 自己抗原の経口投与による自己免疫疾患の治療法
US5399347A (en) 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
JPH02235823A (ja) 1989-03-09 1990-09-18 Watanabe Mitsuko 抗アレルギー剤
JP2891485B2 (ja) 1989-09-25 1999-05-17 科学技術振興事業団 移植拒絶反応抑制剤
ES2144398T3 (es) 1989-12-20 2000-06-16 Autoimmune Inc Tratamiento mejorado de enfermedades autoinmunes mediante la administracion en aerosol de autoantigenos.
EP0594607B1 (de) 1990-03-02 1997-08-27 Autoimmune, Inc. Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
CA2050425A1 (en) 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
JP3198390B2 (ja) * 1990-09-03 2001-08-13 武田薬品工業株式会社 経粘膜用製剤
IL99864A (en) 1990-10-31 2000-11-21 Autoimmune Inc Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens
JP3712260B2 (ja) 1992-02-28 2005-11-02 オートイミューン インク 自己免疫疾患のバイスタンダー抑制
US5453272A (en) 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
JP3109328B2 (ja) 1993-05-19 2000-11-13 ウシオ電機株式会社 加熱定着装置
EP0705108A4 (de) 1993-06-02 1997-08-06 Tvw Telethon Inst Child Health Verwendung von kryptischen peptiden zur induktion immunologisches toleranz
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
JP2847695B2 (ja) * 1994-05-11 1999-01-20 田辺製薬株式会社 血糖降下剤
JP2847696B2 (ja) * 1994-05-11 1999-01-20 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
IL111866A (en) 1994-12-04 2005-03-20 Yeda Res & Dev Pharmaceutical compositions comprising the b-oligomer of pertussis toxin
MX9705198A (es) 1995-01-10 1997-12-31 Fibrogen Inc Metodos y formulaciones a base de colagena para el tratamiento de enfermedades mediadas por el sistema inmune.
AU6113896A (en) 1995-06-05 1996-12-24 Brigham And Women's Hospital Use of oral tolerance to suppress both th1 and th2 immune re sponses and to suppress antibody production
GB9513733D0 (en) * 1995-07-05 1995-09-06 Univ Bristol Therapeutic agents

Also Published As

Publication number Publication date
WO1998047529A1 (en) 1998-10-29
DE69830900D1 (de) 2005-08-25
DK0977586T3 (da) 2005-12-05
EP0977586A1 (de) 2000-02-09
JP2001523249A (ja) 2001-11-20
US7097845B2 (en) 2006-08-29
AU7161098A (en) 1998-11-13
EP0977586B1 (de) 2005-07-20
DE69830900T2 (de) 2006-05-24
US20020119159A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
ATE299711T1 (de) Immunologische toleranz induzierende zusammensetzungen enthaltend antigen und mukosale bindende verbindungen
MX9301716A (es) Una composicion farmaceutica que tiene un sistema definido de lipidos.
DE69837324D1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
MX9702865A (es) Agentes estrogenicos.
FI972945A0 (fi) Antigeenien antamiseen soveltuvia koostumuksia
TW272195B (de)
TR200101822T2 (tr) Kontrollü salınan galantamin bileşimi
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
NZ306653A (en) Isolated dna il-17 receptors
DK0588578T3 (da) Immunogener
FR2703051B1 (fr) Nouvelles pyridothiadiazines, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
WO1998046270A3 (en) Polymeric conjugates polyvalently presenting an agent for therapy
BR0208017A (pt) Combinação compreendendo combretastatina e agentes anticâncer
DK0789590T3 (da) Chitosaninduceret immunforstærkning
KR960702320A (ko) 감마 인터페론의 안정한 액체 조성물 (Stable Liquid Compositions of Gamma Interferon)
DE69231384D1 (de) Zusammensetzungen zur behandlung des chronischen erschöpfungs-syndroms
DE60113664D1 (de) Zusammensetzung zur behandlung von herzinsuffizienz
ES2182975T3 (es) Nueva quimica heterociclica.
DK0972521T3 (da) Farmaceutisk præparat, der indeholder interferon-gamma-stimulatorer
DE59303446D1 (de) Neue bis-phenyl-hexene
DK0817643T3 (da) Forbindelser og præparater til administration af aktive midler
AUPO347396A0 (en) Synergistic gold-containing compositions
EP0819432A4 (de) Antitumormittel mit silizium und stickstoff enthaltenden verbindungen als hauptbestandteil

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 0977586

Country of ref document: EP